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Somatotropins
HISTORICAL DEVELOPMENT
In the early 1930s, it was reported that injections of crude pituitary ex-
tracts increased growth rates in growing animals and milk production 
in lactating animals. Subsequent studies led to purification from pitui-
tary extracts of two peptide hormones—prolactin and “growth hor-
mone” or somatotropin—which are important to growth and lacta-
tion. Prolactin has many functions ranging from regulation of limb re-
generation and salt balance in amphibians to regulation of mammary 
growth and function in many mammals. It was named prolactin be-
cause it was measured (assayed) on the basis of stimulation of mam-
mary growth in rabbits and rodents. Similarly, the term growth hor-
mone arose from the original assay method which was based on 
growth promotion. When it became evident that “growth hormone” 
had many actions in addition to growth promotion, its name was 
changed to somatotropin. The name prolactin has not been changed to 
better describe its diverse functions.
Early investigators, working with rodents and rabbits, demonstra-
ted that prolactin was essential to mammary development during 
pregnancy and to maintenance of lactation. Without replacement 
therapy with both prolactin and cortisol, lactation in rats without a 
pituitary (hypophysectomized) is severely depressed and, as a result, 
their pups lose weight and many die. These observations led to the 
general view that prolactin was “the” pituitary hormone essential to 
lactation even though early publications indicated that somatotropin
was active in enhancing milk production in ruminants while prolactin 
was not. Hormone preparations used during this period were not pure 
and we knew little of species specificity. This caused considerable con-
fusion regarding apparent interspecific differences. Also, most experi-
ments on lactation were conducted using intact animals where results 
are more difficult to interpret than those obtained from animals in 
which confounding effects of endogenous secretions are prevented by 
removal of appropriate endocrine glands. The critical experiment 
which established the essentiality of somatotropin for lactation in ru-
minants was conducted by Cowieer al. (1964). Using hypophysecto- 
mized, lactating goats, they found that somatotropin was essential to 
the maintenance of lactation while prolactin was not.
This and many other studies cited by Hart et al. (1979), and Bauman 
and McCutcheon (1986) had established by the mid 1960s that soma-
totropin enhances growth and lactation in farm animals. Application 
of this knowledge in the animal industry awaited developments in bio-
technology required to produce an adequate supply of somatotropin.
CHEMISTRY OF SOMATOTROPINS
Somatotropins are large, complex peptide hormones comprised of 
190-199 amino acids. Peptide hormones include insulin, prolactin, 
somatotropin, luteotrophic hormones and follicle stimulating hor-
mones. These hormones differ from steroid hormones such as estro-
gen, progesterone and glucocorticoids in a number of important ways. 
Peptide hormones are proteins with molecular weights ranging from 4 
to 22 kg/mole while steroid hormones are small molecules ranging 
from 0.2 to 0.3 kg/mole. Peptide hormones are not active when admi-
nistered orally while steroid hormones are. For example, insulin must 
be injected into diabetics requiring hormone therapy while birth con-
trol pills containing estrogen and progesterone can be taken orally. 
This is because peptide hormones cannot be absorbed until they are 
degraded to their component amino acids in the digestive tract (as 
with all proteins) while steroid hormones are small and readily absorb-
ed, unchanged by the digestive tract. Because peptide hormones are 
highly complex, they and their activities vary greatly across species. 
Homology among peptide hormones is a measure of similarity in ami-
no acid sequences between two peptides. As homology decreases, the 
likelihood that a hormone from one species will act in another species 
decreases. For example, homology between bovine, rat and bovine so-
matotropins is over 85 percent while homology between human soma-
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totropin and bovine somatotropin (BST) is only 70 percent. As a result, 
BST is active in sheep and rats and completely inactive in supporting 
growth when injected into humans. Steroid hormones differ from spe-
cies to species but the differences are small, for example, estrogens 
from one species or estrogen analogues such as diethylstilbestrol can be 
expected to be active in all species. A final difference between peptide 
and steroid hormones is that they differ in their mode of action at the 
cellular level. Peptide hormones bind to receptors on the cell mem-
brane and exert their action from that site. Steroid hormones enter the 
cell and are transferred to the nucleus of the cell where they exert their 
action.
REGULATION OF SOMATOTROPIN SECRETION
The regulation of somatotropin secretion is quite complex as shown in 
Fig 1. As is true for most pituitary hormones, primary control is depen-
dent upon the balance between a releasing factor (growth hormone 
releasing hormone [GHRH]) which stimulates secretion and an inhibi-
ting factor (somatostatin or somatotropin release inhibiting factor 
[SRIF]) which decreases secretion. Growth hormone releasing hor-
mone is a peptide comprised of 48 amino acids and is secreted by the 
hypothalamus or lower brain. Injection of GHRH increases somatotro-
Figure 1
Diagrammatic representation of the regulation of somatotropin secretion and 
actions.
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pin secretion and, indeed, has been considered as an alternative to ad-
ministration of somatotropin to enhance growth and milk production. 
Conversely, formation of antibodies against SRIF, a peptide of 28 ami-
no acids; to reduce SRIF levels results in increased somatotropin re-
lease and can enhance growth. This approach has also been considered 
as an alternative to somatotropin administration. A number of addi-
tional peptides, neurotransmitters and other compounds including 
opiates modify somatotropin release either directly or by modifying 
GHRH and/or somatostatin secretion or action (Fig 1). Opportunities 
for modification of somatotropin secretion through manipulation of 
these “other” factors undoubtedly exist but have not been explored 
thoroughly.
mechanism (s ) of  somatotropin  action
Administration of somatotropin, specific to a given species, clearly en-
hances growth rate (ADG) and efficiency (feed/gain) in farm livestock 
favoring protein over fat accretion at lower feed intakes. It is just as 
clear that BST administration enhances milk production in dairy cat-
tle. Mechanisms whereby somatotropins produce these responses are 
not fully understood and, thus, any discussion of mechanism (below) 
must contain some speculation.
Several mechanisms involved in growth promotion by somatotro-
pin are summarized in Figure 1. It is now clear that a primary action of 
somatotropin is to enhance the formation and secretion of insulin-like 
growth factor 1 (IGF-1) by the liver. Insulin-like growth factor 1 is 
also called somatomedin C (SmC) to indicate that it mediates somato-
tropin action. Circulating levels of somatotropin do not differ between 
toy and standard poodles but amounts of IGF1 secreted by the liver do 
differ causing the differences in size. This illustrates the essential role 
IGF-1 secretion by the liver in muscle and, probably, acts to increase 
rates of protein accretion by increasing rates of protein synthesis. The 
increase in the rate of protein synthesis may be a direct effect on bio-
synthetic capacity in muscle cells or an indirect effect due to increased 
satellite cell proliferation leading to increased numbers of nuclei per 
muscle cell which, in turn, increases biosynthetic capacity.
Until recently, it was considered anomalous that circulating levels 
of somatotropin become elevated during fasting in many species. The 
effect somatotropin has upon adipose tissue is to increase capacity for 
fat mobilization (Iipolysis). This was considered consistent with ele-
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vated somatotropin, the need for fat mobilization during fasting and 
reduced fat accretion in fed animals injected with somatotropin. How-
ever, IGF—1 stimulates fat synthesis (lipogenesis) and storage. There-
fore, if somatotropin increases circulating levels of IGF—1, one would 
expect the lipogenic effects of IGF—1 to counterbalance the lipolytic 
effects of somatotropin in adipose tissue. Now, we know that liver cell 
membrane receptors required for somatotropin binding in liver de-
crease during fasting, such that the elevated somatotropin levels are 
not recognized by liver and IGF—1 secretion is not increased. Thus, 
during fasting somatotropin increases, thereby increasing lipolytic 
capacity in adipose tissue but IGF—1 secretion by liver and adipose lipo-
genic capacity are not increased so the net response in adipose tissue is 
mobilization of fat.
With respect to lactation, the exact mechanism(s) of BST action are 
not known but some insight is emerging. Three major factors control 
milk production by the mammary glands: blood nutrient concentra-
tions, blood flow to the udder, and biosynthetic capacity of the udder. 
Although fatty acids in blood increase slightly when somatotropin is 
injected into cows in early lactation, changes in blood nutrient concen-
tration due to somatotropin administration are small or absent and 
certainly not sufficient to explain the increase in milk production 
reported (Bauman and McCutcheon, 1986). Blood flow to the udder 
increases in parallel with milk production while arteriovenous diffe-
rences (uptake) of nutrients from blood remain relatively constant. 
Thus, it appears logical to conclude that mammary metabolic/biosyn- 
thetic capacity is increased by BST treatment resulting in increased 
product concentrations in venous blood and, in turn, a demand for 
greater blood flow. Current thoughts are that the effect of BST upon 
milk production is mediated by IGF-1 and is due, at least in part, to 
increased numbers of secretory cells, increased biosynthetic capacity 
per secretory cell or both of these.
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